Parabilis Medicines to present updated zolucatetide trial data in desmoid tumors at ESMO 2026

PBLS•2026-10-19

Parabilis Medicines will present updated Phase 1/2 zolucatetide desmoid tumor data at the ESMO Congress in Madrid on October 24, 2026. The presentation will include safety and efficacy findings from dose escalation and optimization, with a June 22, 2026, data cutoff.

Parabilis Medicines to present updated zolucatetide trial data in desmoid tumors at ESMO 2026

1. Trial data presentation

2. Dose selection plans

Related News

BrainsWay receives multisystem order from Inland Psychiatric Medical Group

Nasdaq trade halt continues; reason not available at 7:55 am

Glass House Brands director John Nichols Jr. resigns

Biogen's Empaveli sustains proteinuria reduction, stabilizes kidney function over 76 weeks

Centrus acquires Westerman Holdings for $116 million